16 ML bevacizumab-maly 25 MG/ML Injection [Alymsys]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
16 ML bevacizumab-maly 25 MG/ML Injection [Alymsys]
25 MG/ML · Injection · injection
A form of bevacizumab-maly →
16 ML bevacizumab-maly 25 MG/ML Injection [Alymsys] — VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors. Strength, form, class, interactions & more.
![16 ML bevacizumab-maly 25 MG/ML Injection [Alymsys]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=42b4f96e-1f70-2126-e063-6294a90a93e3&name=alymsys-bevacizumab-maly-injection-1.jpg)
Active ingredient
Classification
VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsVascular Endothelial Growth Factor Inhibitor
Drug interactions
No clinically meaningful effect on the pharmacokinetics of certain drugs was observed when administered with bevacizumab, although some patients experienced lower drug exposure after treatment.
- unknownirinotecan — No clinically meaningful effect on pharmacokinetics observed.
- unknownSN38 — No clinically meaningful effect on pharmacokinetics observed.
- unknowninterferon alfa — No clinically meaningful effect on pharmacokinetics observed.
- unknowncarboplatin — No clinically meaningful effect on pharmacokinetics observed.
- moderatepaclitaxel — No clinically meaningful effect on pharmacokinetics observed, but lower exposure noted in some patients after treatment.
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication